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INTRODUCTION
Recent treatment guidelines and algorithms for the man-
agement of chronic hepatitis B (CHB) take into account the
importance of prolonged viral suppression in terms of prevent-
ing disease progression and hepatocellular carcinoma (HCC)
development (1-3). Currently available oral nucleos(t)ide ana-
logues (NUC) for the treatment of CHB include lamivudine,
adefovir, entecavir, telbivudine, and recently tenofovir (3).
Although NUCs are more convenient than interferon-based
therapies and have fewer side effects, sustained viral suppres-
sion is usually not achieved after a 48-week course of NUC
therapy, which necessitates long, and in many cases, indefi-
nite treatment (1). Unfortunately, protracted NUC treatment
is associated with an elevated risk of development drug resis-
tance (4). Developments of new antiviral agents and regimens
remain an important focus in terms of improving reductions
in viral loads and resistance profiles.
Clevudine (1-[2-doxy-2fluoro-b-L-arabinofuranosyl] thy-
mine, L-FMAU) is a novel pyrimidine nucleoside analogue
with an unnatural b-L configuration and potent antiviral activ-
ity in vitro and in a woodchuck model (5, 6). In a phase I/II
dose-escalating clinical study and in a randomized phase II
clinical trial, 4-week and 12-week clevudine therapy induced
potent viral suppression at an optimal dosage of 30 mg once
daily (7-9). In randomized phase III clinical trials, 24-week
clevudine therapy showed a potent antiviral effect and produc-
ed significant biochemical improvements without evidence
of viral resistance during the treatment period in HBeAg-
positive and HBeAg-negative CHB (10, 11). The ability to
maintain antiviral activity in a significant proportion of pati-
ents following the discontinuation of therapy is a unique char-
acteristic of clevudine. The above results show that clevudine
is probably one of the most potent antivirals available for the
treatment of hepatitis B virus (HBV). Clevudine is already
licensed in Korea for anti-HBV therapy (Bukwang Pharma-
ceuticals, Seoul), but previous clinical trials were placebo-con-
trolled studies of relatively short treatment duration. Accord-
ingly, we need to determine the longer-term treatment out-
comes of clevudine therapy and to determine whether clevu-
dine is superior to the preexisting oral NUC, lamivudine.
The aim of this study was to compare the antiviral effica-
cies and resistances of clevudine and lamivudine after 48 weeks
of administration in naı ¨ve patients with hepatitis B e anti-
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Treatment Outcomes of Clevudine versus Lamivudine at Week 48 
in Naive Patients with HBeAg Positive Chronic Hepatitis B
The authors assessed the efficacy and antiviral resistance of 48-week clevudine
therapy versus lamivudine in treatment of na¨ ıve patients with HBeAg positive chron-
ic hepatitis B. In this retrospective study, a total of 116 HBeAg positive patients, who
received 30 mg of clevudine once daily (n=53) or 100 mg of lamivudine once daily
(n=63) for 48 weeks, were included. At week 48, clevudine therapy produced a sig-
nificantly greater mean reductions in serum HBV DNA levels from baseline than
lamivudine therapy (-5.2 vs. -4.2 log10IU/mL; P=0.005). Furthermore, a significantly
higher proportion of patients on clevudine achieved negative serum HBV DNA by
PCR (<13 IU/mL) at week 48 (60.4% vs. 38.1%; P=0.025). The incidence of viro-
logic breakthrough in the clevudine group was significantly lower than in the lamivu-
dine group (9.4% vs. 25.4%; P=0.031). However, rates of alanine aminotransferase
normalization and HBeAg loss or seroconversion were similar in the two groups
(83.0% vs. 81.0%, 11.3% vs. 11.1%; P=0.813, 1.000, respectively). In conclusion,
clevudine is more potent for viral suppression and lower for antiviral resistance at
week 48 than lamivudine in treatment of na¨ ıve patients with HBeAg positive chron-
ic hepatitis B.
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gen (HBeAg) positive CHB. In addition, we also analyzed
associations between early viral suppression during therapy
and 48 week treatment outcomes.
MATERIALS AND METHODS
Patients
This was an open-labeled, retrospective, nonrandomized,
comparative study. Data were collected from the medical
records of all patients with CHB treated with clevudine or
lamivudine at two tertiary referral hospitals, namely, Chon-
buk National University Hospital and Wonkwang Univer-
sity Hospital, between January 2007 and December 2008.
Patients with CHB who received either 30 mg of clevudine
orally once daily or 100 mg of lamivudine orally once daily
for at least 48 weeks were included in this analysis. Patients
were eligible if they were 18-70 yr of age and had HBeAg
positive CHB or compensated liver cirrhosis. CHB was defin-
ed as a detectable serum hepatitis B surface antigen (HBsAg)
level for more than 6 months, a serum HBV DNA level greater
than 105 copies/mL (or ≥20,000 IU/mL), and a serum ala-
nine aminotransferase (ALT) level 1.5-10 times the upper
limit of normal. Liver cirrhosis was demonstrated mainly by
ultrasonography (i.e., a coarse liver architecture, a nodular
liver surface, and blunt liver edges) and evidence of hyper-
splenism (i.e., splenomegaly on ultrasonography and a platelet
count of <100,000/mL). Patients with decompensated liver
disease or biochemical signs of renal impairment (a serum
creatinine of ≥1.5 mg/dL or a creatinine clearance of <50
mL/min, as determined by the Cockroft method) were exclud-
ed. The other exclusion criteria applied were as follows: prior
treatment with anti-HBV NUCs or interferon; coinfection
with human immunodeficiency virus, hepatitis C virus, or
hepatitis delta virus; a history of alcohol or drug abuse with-
in the preceding 2 yr; documented or suspected HCC; prior
organ transplantation; or pregnancy/lactation.
A total of 116 patients were included in this analysis. Fifty-
three patients were treated with clevudine for 48-96 (medi-
an 71.2) weeks and sixty-three with lamivudine for 48-108
(median 82.4) weeks. Routine blood tests and liver enzymes
were performed every 3 months and adverse events were assess-
ed at each visit. Liver panel, creatinine, HBeAg, anti-HBe,
and quantitative HBV DNA were checked at commencement
of therapy, and then every 3 months in all patients. All 116
patients were included in the analysis of treatment outcomes
at 24 and 48 weeks. The myopathy associated with clevudine
therapy has not been well defined by previous clinical trials,
and therefore, serum creatine kinase (CK) was not checked
regularly during this study. Only patients who presented with
progressive proximal muscular weakness were tested for serum
CK level. This study was conducted in compliance with the
World Medical Association Declaration of Helsinki and was
approved by the Ethics Committee at our institution (CBIRB
1003-30).
Serum assays
HBsAg, anti-HBs, HBeAg, and anti-HBe were detected
using commercial enzyme-linked immunosorbent assay (EL-
ISA) kits (AXSYM, Abbott Laboratories, Chicago, IL, USA).
Serum HBV DNA levels were determined using polymerase
chain reaction (PCR) assays (mainly real-time PCR assays)
using the COBAS TaqMan HBV Test (Roche Diagnostics,
Branchberg, NJ, USA; detection limit 13 IU/mL). In a small
proportion of patients, the COBAS Amplicor HBV Monitor
Test (Roche Diagnostics) with a detection limit of 300 copies/
mL was used to quantify serum HBV DNA level at baseline.
We rechecked serum HBV DNA levels by real-time PCR
in patients with an undetectable HBV DNA level using the
Amplicor PCR assay during treatment. The World Health
Organization (WHO) has established an international refer-
ence standard for HBV DNA testing based on IU/mL (12).
To compare serum HBV levels expressed in different units,
we converted ‘copies/mL’ of serum HBV DNA levels to ‘IU/
mL’ using (1 IU/mL=5.6 copies/mL), which was provided
by the manufacturer (13).
Genotypic analysis of HBV DNA polymerase was per-
formed in patients showing virologic breakthrough during
therapy using a matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) based
genotyping assay, termed the Restriction Fragment Mass
Polymorphism (RFMP) assay, as previously described (14).
Efficacy endpoints and definitions
The primary endpoints of this study were a reduction in
serum HBV DNA at week 48 versus baseline, and the pro-
portions of patients that achieved undetectable serum HBV
DNA levels by PCR (<13 IU/L) and serum ALT normaliza-
tion (≤40 IU/L). The secondary endpoints included the pro-
portion of patients showing HBeAg loss or seroconversion,
primary treatment failure, and virologic breakthrough. Pri-
mary treatment failure was defined as the inability of antivi-
ral treatment to reduce serum HBV DNA by ≥1 log10IU/
mL after the first 3 months of treatment (15). Virologic break-
through, which is usually associated with drug resistance, was
defined as a ≥1 log10IU/mL increase in serum HBV DNA
level from its nadir in two consecutive samples 1 month apart
while on treatment, after achieving an initial response, in med-
ically compliant patients on antiviral medication(s) (15).
Data from all study subjects were pooled, regardless of treat-
ment group, and subjects were categorized according to serum
HBV DNA level at week 24; undetectable (<13 IU/mL), from
13 to <200 IU/mL, from 200 to <2,000 IU/mL, and ≥2,000
IU/mL. Treatment outcomes at week 48, including, HBV
DNA non-detectability, HBeAg loss or seroconversion, ALT740 I.H. Kim, S. Lee, S.H. Kim, et al.
normalization, and viral breakthrough were analyzed accord-
ing to residual serum HBV DNA category at week 24.
Statistical analysis
Results are reported as means±standard deviations (SD).
HBV DNA levels were logarithmically transformed for anal-
ysis. Continuous variables were compared using the 2-tailed
Student’s t-test. Categorical data were analyzed using the chi-
square test or Fisher’s exact test. Factors associated with viral
breakthrough were analyzed by univariate analysis and mul-
tivariate logistic regression analysis. P values of <0.05 were
considered statistically significant. Data was collated in Mic-
rosoft EXCEL (Microsoft Excel 2003; Microsoft Corporation,
Seattle, WA, USA), and analyzed using SPSS for Windows
(version 15.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the patients
Of the 116 patients, 85 (73.3%) were male with a mean
age of 40.2 yr and 12 (10.3%) patients had compensated cir-
rhosis. The two treatment groups were comparable with res-
pect to demographic and baseline laboratory features, includ-
ing age, sex, presence of cirrhosis, serum ALT level, and serum
HBV DNA level (Table 1).
Treatment responses
Serum HBV DNA levels declined markedly after treatment
commencement in both treatment groups. Clevudine had a
more potent antiviral effect at week 24, and subsequently the
mean reduction in serum HBV DNA level remained consis-
tently greater in the clevudine group than in the lamivudine
group (Fig. 1). At week 24, mean reductions of serum HBV
DNA levels from baseline were -5.0 vs. -4.2 log10IU/mL in
the clevudine and lamivudine groups, respectively (P=0.007).
Furthermore, mean reduction of serum HBV DNA level from
baseline at week 48 was significantly greater in the clevudine
group (-5.2 vs. -4.2 log10IU/mL; P=0.005) and a significantly
higher proportion of patients on clevudine achieved negative
serum HBV DNA by PCR (<13 IU/mL) at week 48 (60.4%
vs. 38.1%; P=0.025) (Table 2). Group distributions of pati-
ents according to serum HBV DNA levels at weeks 24 and
48 are shown in Fig. 2. At week 24, more patients in the cle-
vudine group than in the lamivudine group were non-detec-
table for serum HBV DNA level by PCR (<13 IU/mL), where-
as residual serum HBV DNA levels greater than 2,000 IU/
mL were more frequent in patients in the lamivudine group
than in those in the clevudine group (P=0.041). The distri-
bution of patients according to HBV DNA levels at week
Data are expressed as means±SDs or percentages.
*All patients had compensated cirrhosis.
GGT, gamma glutamyl transpeptidase; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; HBV, hepatitis B virus.
Parameters
Clevudine group
(n=53)
Lamivudine
group (n=63)
P value
Mean age (yr) 40.4±10.9 39.9±11.2 0.814
Male sex, n (%) 38 (71.7) 47 (74.6) 0.725
Cirrhosis*, n (%) 5 (9.4) 7 (11.1) 0.768
Platelet (×10
3/mL) 178.8±51.2 176.8±62.1 0.856
GGT (IU/L) 110.0±134.8 94.9±86.3 0.479
AST (IU/L) 134.4±166.0 141.7±107.5 0.774
ALT (IU/L) 207.5±205.3 235.9±216.5 0.473
Total bilirubin (mg/dL) 1.1±0.9 1.1±0.7 0.893
Albumin (g/dL) 4.1±0.4 4.2±0.4 0.630
Creatinine (mg/dL) 1.0±1.3 0.8±0.2 0.273
Serum HBV DNA  7.2±0.8 7.2±0.9 0.964
(log10IU/mL)
Table 1. Baseline characteristics of patients
Fig. 1. Mean reductions of serum HBV DNA levels during the study
period. At weeks 24, 36, and 48, clevudine therapy produced a
significantly greater mean reduction in serum HBV DNA level from
baseline than lamivudine therapy
*P=0.007; 
� P<0.001; and 
� P=0.005, respectively.
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Data are expressed as means±SDs or percentages.
HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepati-
tis B e antigen.
Variables
Clevudine 
group 
(n=53)
Lamivudine
group
(n=63)
P
value
Serum HBV DNA, mean reduction  -5.2±1.7 -4.2±2.0 0.005
from baseline (log10IU/mL)
Serum HBV DNA, PCR negative, n (%) 32 (60.4) 24 (38.1) 0.025
Serum HBV DNA ≤2,000 IU/mL, n (%) 46 (86.8) 37 (58.7) 0.001
ALT normalization, n (%) 44 (83.0) 51 (81.0) 0.813
HBeAg loss or seroconversion 6 (11.3) 7 (11.1) 1.000
Primary treatment failure, n (%) 0 (0.0) 3 (4.8) 0.249
Virologic breakthrough, n (%) 5 (9.4) 16 (25.4) 0.031
Table 2. Efficacy of antiviral therapies in HBeAg positive patients
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48 was also consistent with the greater early viral suppres-
sion observed with clevudine (P=0.002).
However, clevudine and lamivudine treated patients had
similar biochemical and serological responses. At week 48,
83.0% in the clevudine group and 81.0% in the lamivudine
group had achieved serum ALT level normalization (P=0.813),
and the rate of HBeAg loss and/or HBeAg seroconversion
was 11.3% in the clevudine group and 11.1% in the lamivu-
dine group (P=1.000) (Table 2).
Virologic breakthrough and resistance
Five (9.4%) of the 53 clevudine treated patients and 16
(25.4%) of the 63 lamivudine treated patients showed viro-
logic breakthrough during the 48-week treatment period.
The clevudine group had a significantly lower rate of viro-
logic breakthrough than the lamivudine group (P=0.031)
(Table 2). In addition, three (4.8%) patients in the lamivu-
dine group but no patient in the clevudine group showed
primary treatment failure (P=0.249).
Mutations associated with resistance to clevudine and lamivu-
dine were analyzed using RFMP assays in all patients that
developed viral breakthrough during therapy. Of the 5 pati-
ents in the clevudine group with viral breakthrough, 4 pati-
ents had the rtM204I mutation alone and one patient har-
bored rtM204I+rtL180M mutations. Of the 16 patients in
the lamivudine group with viral breakthrough, 8 patients had
rtM204V±rtL180M mutations, 7 patients had rtM204I
mutation±tL180M mutations, and one patient had the
rtM204I+rtM204V+rtL180M mutations.
Factors associated with virologic breakthrough
We assessed factors associated with virologic breakthrough
over the 48-week treatment period by univariate analysis
(Table 3). In the clevudine group, age, sex, presence of cir-
rhosis, baseline serum ALT and baseline serum HBV DNA
levels, and serum HBV DNA level (≥2,000 IU/mL at week
24) were not found to be associated with virologic break-
through. However, in the lamivudine group, virologic break-
through was found to be associated with a high baseline serum
HBV DNA level (P=0.001), and a serum HBV DNA level
of ≥2,000 IU/mL at week 24 (P=0.014).
We also analyzed factors associated with virologic break-
Fig. 2. Patient distributions with respect to serum HBV DNA levels. The distributions of patients according to HBV DNA levels at week 24
and 48 were consistent with the greater viral suppression observed with clevudine (*P=0.041 and 
� P=0.002, respectively).
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Clevudine group (n=53)
Variables With V-BT*
(n=5)
Without V-BT
(n=48)
P
Lamivudine group (n=63)
With V-BT*
(n=5)
Without V-BT
(n=48)
P
Age (yr) 44.6±9.1 40.0±11.0 0.367 41.0±10.8 39.5±13.4 0.686
Male sex, n (%) 3 (60.0) 35 (72.9) 0.614 11 (68.8) 36 (76.6) 0.525
Cirrhosis, n (%) 0 (0.0) 5 (11.5) 0.590 1 (6.3) 6 (12.8) 0.667
Baseline serum ALT (IU/L) 174.4±156.9 211.0±215.0 0.708 172.9±131.7 257.4±235.9 0.180
Baseline serum HBV DNA (log10IU/mL) 7.5±0.4 7.2±0.9 0.475 7.7±0.5 7.0±1.0 0.001
Serum HBV DNA at week 24  3 (60.0) 11 (22.9) 0.108 10 (62.5) 12 (25.5) 0.014
≥2,000 IU/mL, n (%)
Table 3. Factors associated with virologic breakthrough during the 48-week treatment period742 I.H. Kim, S. Lee, S.H. Kim, et al.
through by logistic regression analysis after pooling data from
all study subjects (Table 4). It was found that baseline serum
HBV DNA level (odds ratio 3.13, 95% confidence interval
1.22-7.99; P=0.017), serum HBV DNA level at week 24
(≥2,000 IU/mL vs. <2,000 IU/mL) (odds ratio 3.87, 95%
confidence interval 1.28-11.74; P=0.017), and treatment
type (lamivudine vs clevudine) (odds ratio 3.86, 95% confi-
dence interval 1.16-12.82; P=0.027) were significantly asso-
ciated with virologic breakthrough.
Effect of early virologic response on treatment outcomes
at week 48
Data from all study subjects were pooled, and categorized
according to serum HBV DNA level at week 24. Treatment
outcomes at week 48 were found to be strongly associated
with degree of viral suppression at week 24 (Fig. 3). As shown
in Fig. 3, the likelihood of HBV DNA becoming undetec-
table at week 48 was found to be inversely related to viral
load at week 24. Furthermore, 32 (94.1%) of the 34 patients
with an undetectable HBV DNA level by PCR (<13 IU/mL)
at week 24 maintained an undetectable HBV DNA level at
week 48, whereas only 3 (8.3%) of 36 patients with a serum
HBV DNA level ≥2,000 IU/mL at week 24 achieved an
undetectable HBV DNA level at week 48. Rates of HBeAg
loss or seroconversion and ALT normalization at week 48 were
also higher in patients with a non-detectable serum HBV
DNA level at week 24 than in patients with a residual viral
load of ≥2,000 IU/mL (23.5% vs. 0%, 88.2% vs. 66.7%, res-
pectively). Moreover, at week 48, viral breakthrough occurred
in only 1 (2.9%) of 34 patients with a non-detectable HBV
DNA level at week 24, as compared with 13 (36.1%) of 36
patients with residual viremia of ≥2,000 IU/mL at week 24.
Safety and adverse events
During the treatment period, no specific serious adverse
event was encountered in any patient. Adverse events occurred
with similar frequencies in both groups. The most frequent
adverse events in both groups were; fatigue, upper respira- HBV, hepatitis B virus.
Variables
Odds 
ratio
95% Confi-
dence Interval
P
Baseline serum HBV DNA 3.13 1.22-7.99 0.017
(log10IU/mL)
Serum HBV DNA at week 24  3.87 1.28-11.74 0.017
≥2,000 IU/mL vs. <2,000 IU/mL
Treatment, clevudine vs. lamivudine 3.86 1.16-12.82 0.027
Table 4. Multivariate analysis for factors associated with virolog-
ic breakthrough
Fig. 3. Effect of early viral response on treatment outcomes at week 48. Treatment outcomes at week 48 were found to be strongly asso-
ciated with degree of viral suppression at week 24.
94.1
R
e
s
p
o
n
s
e
 
a
t
 
w
e
e
k
 
4
8
 
(
%
)
100
90
80
70
60
50
40
30
20
10
0
Undetectable 13-200 200-2,000 ≥2,000
Serum HBV DNA level at week 24 (IU/mL)
Undetectable levels of HBV DNA
54.5
37.5
8.3
23.5
R
e
s
p
o
n
s
e
 
a
t
 
w
e
e
k
 
4
8
 
(
%
)
100
90
80
70
60
50
40
30
20
10
0
Undetectable 13-200 200-2,000 ≥2,000
Serum HBV DNA level at week 24 (IU/mL)
HBeAg loss/seroconversion
22.7
0.0 0.0
88.2
R
e
s
p
o
n
s
e
 
a
t
 
w
e
e
k
 
4
8
 
(
%
)
120
100
80
60
40
20
0
Undetectable 13-200 200-2,000 ≥2,000
Serum HBV DNA level at week 24 (IU/mL)
ALT normalization
81.8
95.8
66.7
2.9
R
e
s
p
o
n
s
e
 
a
t
 
w
e
e
k
 
4
8
 
(
%
)
100
90
80
70
60
50
40
30
20
10
0
Undetectable 13-200 200-2,000 ≥2,000
Serum HBV DNA level at week 24 (IU/mL)
Viral breakthrough
9.1
20.8
36.1Clevudine Versus Lamivudine in HBeAg Positive Chronic Hepatitis B 743
tory symptoms, headache, and dyspepsia. However, all symp-
toms were mild and relatively well tolerated. No significant
changes were observed over the treatment period in serum
creatinine or in any other laboratory parameter, and no pati-
ent with cirrhosis in either group experienced hepatic decom-
pensation.
DISCUSSION
In this retrospective study, clevudine (30 mg daily for 48
weeks) showed potent antiviral activity in HBeAg positive
CHB patients. In particular, it suppressed mean serum HBV
DNA by -5.2 log10IU/mL during the 48-week treatment
period, and 60.4% of clevudine treated patients had an unde-
tectable serum HBV DNA level by PCR assay after treat-
ment. Although this study was not randomized and the study
groups were not matched on a patient-to-patient basis, the
degree of HBV DNA reduction achieved by clevudine at 30
mg daily at week 48 was found to be significantly greater than
that achieved by lamivudine at 100 mg daily (-5.2 log10IU/
mL vs. -4.2 log10IU/mL; P=0.005). Furthermore, the propor-
tion of patients that achieved a non-detectable serum HBV
DNA level by PCR (<13 IU/mL) at week 48 was also sig-
nificantly greater in the clevudine group (60.4% vs. 38.1%;
P=0.025). Clevudine also showed potent early virologic res-
ponse, and this was greater than that achieved by lamivudine.
At week 24, mean serum HBV DNA reductions from base-
line and the proportion of patients with a serum HBV DNA
level of <2,000 IU/mL at week 24 were also significantly
greater in the clevudine group. In a previous 24-week clevu-
dine treatment study (11), 68.2% of patients achieved serum
ALT normalization, which concurs with the high normaliza-
tion rate of 83.3% at week 48 found in the present study.
However, despite the more potent antiviral suppression of
clevudine, clevudine and lamivudine induced similar bio-
chemical and serological responses.
The presence of drug-resistant mutations is a primary con-
cern when considering oral NUC therapy. In previous 24-
week treatment trials, clevudine showed no virologic break-
through (10, 11). In contrast, during the present 48-week
study, virologic breakthrough occurred in 9.4% of clevudine
treated patients. When we compared this with that of the
lamivudine group, it was found that the incidence of viro-
logic breakthrough was significantly lower in the clevudine
group (9.4% vs. 25.4%; P=0.031). A recent study from Korea
found that rates of viral breakthrough at 1 yr were 10.0%
in treatment naı ¨ve patients and 44.4% in patients with a his-
tory of previous lamivudine treatment (P<0.001) (16). These
results indicate that viral breakthrough during clevudine ther-
apy is not negligible in treatment naı ¨ve CHB patients. Fur-
thermore, previous lamivudine treatment was found to be
associated with a substantially higher rate of viral breakthrough,
which may have been due to an increased risk of cross resis-
tance between two drugs. Therefore, care is required when
clevudine is administered to patients previously treated with
lamivudine. In addition, the cumulative incidence of clevu-
dine resistance is likely to increase with therapy duration. More
long-term studies are needed to understand the cumulative
incidences and clinical effects of resistance to clevudine.
Our resistance profiles confirm that the rtM204I mutation
is the primary clevudine resistance mutation. Lee et al. also
reported that rtM204I is most common mutation of HBV
DNA polymerase in treatment naı ¨ve patients; other sites of
mutation were rtL80I, rtL180M, rtA181V/T, rtV207I (16).
Furthermore, the rtM204I mutation is cross resistant with
other L-nucleosides, such as, lamivudine, emtricitabine, and
telbivudine (15, 17). In vitro studies have demonstrated that
adefovir, tenofovir, and entecavir have antiviral activity against
L-nucleoside-resistant HBV mutants, but the activity of ente-
cavir against these mutants is substantially lower than against
wild type HBV (17). In previous studies in patients with
lamivudine-resistant CHB, a combination of lamivudine and
adefovir was found to be more effective at preventing subse-
quent adefovir resistance (18, 19). Tenofovir has also been
shown to be effective in patients with HBV resistance to both
lamivudine and adefovir (20), on the other hand, entecavir
monotherapy was found to have a high risk of entecavir resis-
tance in lamivudine-resistant patients (21). Accordingly, the
addition of adefovir or tenofovir may be preferable to switch-
ing to adefovir or entecavir in patients with clevudine-resis-
tant CHB.
We also assessed factors associated with virologic break-
through. By univariate analysis, virologic breakthrough in
the clevudine group was not found to be associated with base-
line factors or early viral response. However, because the num-
ber of patients with virologic breakthrough was small in the
clevudine group, statistical power may have been underesti-
mated. By multivariate analysis after pooling data from all
study subjects, regardless of treatment group, baseline serum
HBV DNA level (odds ratio 3.13, 95% confidence interval
1.22-7.99; P=0.017), serum HBV DNA level at week 24
(≥2,000 IU/mL vs. <2,000 IU/mL) (odds ratio 3.87, 95%
confidence interval 1.28-11.74; P=0.017), treatment type
(lamivudine vs. clevudine) (odds ratio 3.86, 95% confidence
interval 1.16-12.82; P=0.027) were found to be significant-
ly associated with virologic breakthrough.
In the clinical trials of agents with lower genetic barriers
to viral resistance, such as, lamivudine and telbivudine, early
maximal reductions in HBV DNA levels at 24 weeks were
found to predict improved clinical outcomes at 1 and 2 yr
(22-24). Similar trends were observed in the present study.
When we pooled data from all of our study subjects and exam-
ined relations between treatment outcomes at week 48 with
respect to serum HBV DNA levels at week 24, it was found
that treatment outcomes at week 48 were strongly associat-
ed with degree of viral suppression at week 24. Patients with
an undetectable HBV DNA level by PCR at week 24 showed744 I.H. Kim, S. Lee, S.H. Kim, et al.
higher rates of HBV DNA non-detectability, HBeAg loss
or seroconversion, ALT normalization, and a lower rate of
viral breakthrough than those with residual viral viremia of
≥2,000 IU/mL at week 24. The results of the present study
support the utility of the recently proposed ‘roadmap’ concept
as a strategy to improve long-term treatment results (3).
Previous 24-week clinical trials have shown that the inci-
dences of adverse events are similar for patients on clevudine
or placebo (10, 11). We also encountered no meaningful seri-
ous adverse events in either treatment group. However, a recent
study reported that the long-term use of clevudine can induce
mitochondrial DNA depletion and lead to mitochondrial
myopathy associated with myonecrosis (25). Lee et al. also
reported that 10 of 339 (2.9%) patients complained of promi-
nent fatigue and had elevated serum levels of aspartate amino-
transferase and CK after 1 yr of clevudine therapy. Further-
more, two of these patients presented with severe myopathy,
from which they recovered completely after quitting clevu-
dine. We also reviewed the follow up medical records and labo-
ratory data of both treatment groups after 48 weeks. Myopa-
thy, characterized by muscle pain and weakness and moder-
ately elevated CK levels during treatment, was observed in
three (5.7%) of patients in the clevudine group and none of
those in the lamivudine group. All three patients who devel-
oped myopathy during clevudine therapy were treated with
clevudine for more than 52 weeks (52-60 weeks). When cle-
vudine was discontinued, CK levels returned to normal with-
in 2 months and symptoms resolved over a period of 2 to 4
months in all patients. Therefore, we suggest that patients
on long-term clevudine therapy should be monitored care-
fully for skeletal muscle dysfunction.
In conclusion, we found that 48-week clevudine therapy
induced more potent, earlier virologic response and produced
better treatment outcomes at 48 weeks than lamivudine in
patients with HBeAg positive CHB. Nevertheless, viral break-
through was observed during the 48-week clevudine admin-
istration period. Furthermore, treatment outcomes at week
48, in both treatment groups, were found to be strongly asso-
ciated with degree of viral suppression at week 24. The pre-
sent study is limited by its open-label, nonrandomized, retro-
spective design. Accordingly, a longer-term, randomized, con-
trolled clinical trial is needed to confirm our preliminary find-
ings.
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